Up until now, Affichem is 100% owned by physical persons.
Co-founders were joined by business angels and crowdfunding investors.
About half of expenses have been financed by non dilutive resources (collaborative R&D programs, public funds).

In 2015, technological maturity of Affichem products allows the company to initiate a global fund-raising program and study partnership opportunities.

For more information :
info@affichem.com
 
Cancer - Melanoma - Deafness - Neurodegenerative disease - Drug design - Anticancer therapy - Cell differentiation - Receptor - Enzyme - Metabolism - Medicinal chemistry - Biotechnology - First in class molecule - New Chemical Entities - Cholesterol - Tamoxifen - Immunotherapy - Exosome - Oncology - Dendritic cell -